Canakinumab holds promise for treating children with Systemic Juvenile Idiopathic Arthritis

A new interleukin-1 (IL-1)-beta blocking monoclonal antibody, Canakinumab (ACZ885), holds enough promise suggesting efficacy and toleration in children with systemic juvenile idiopathic arthritis (sJIA), as per a new phase II study presented at PReS 2009, a joint congress with the 2009 Congress of the European League against Rheumatism (EULAR) in Copenhagen, Denmark.
Dr Nicolino Ruperto, Senior [...]